Discontinued Operations - Narrative (Details) - USD ($) $ in Millions		12 Months Ended
	Jul. 06, 2021	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (loss) on sale of business		$ 0.0	$ 0.0	$ 47.5
Foreign currency translation gain	$ 159.3
RX Pharmaceuticals | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total consideration in definitive agreement to sell	1,550.0
Potential R&D milestone payments and contingent purchase obligations assumed by purchaser	53.3
Gain (loss) on sale of business	$ 47.5
Separation costs				$ 40.8
Supply agreement term	4 years
Supply agreement, extension period	7 years
Aggregate cap on buyer's obligation for certain pre-closing liabilities (percent)	50.00%
Aggregate cap on buyer's obligation for certain pre-closing liabilities	$ 50.0